Simon Chivers

802 total citations
20 papers, 533 citations indexed

About

Simon Chivers is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Simon Chivers has authored 20 papers receiving a total of 533 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Simon Chivers's work include CAR-T cell therapy research (8 papers), Cancer therapeutics and mechanisms (5 papers) and Synthesis and pharmacology of benzodiazepine derivatives (4 papers). Simon Chivers is often cited by papers focused on CAR-T cell therapy research (8 papers), Cancer therapeutics and mechanisms (5 papers) and Synthesis and pharmacology of benzodiazepine derivatives (4 papers). Simon Chivers collaborates with scholars based in United Kingdom, Switzerland and Germany. Simon Chivers's co-authors include Francesca Zammarchi, Patrick H. van Berkel, Lauren Adams, Simon Corbett, John A. Hartley, Philip W. Howard, Karin Havenith, David G. Williams, Arnaud Tiberghien and Carin E.G. Havenith and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Simon Chivers

20 papers receiving 513 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Simon Chivers United Kingdom 11 286 137 130 126 99 20 533
Winston Evering United States 14 277 1.0× 78 0.6× 309 2.4× 174 1.4× 57 0.6× 21 693
Zhixin Qiu China 20 216 0.8× 62 0.5× 147 1.1× 333 2.6× 64 0.6× 49 790
H Makuuchi Japan 17 358 1.3× 190 1.4× 64 0.5× 189 1.5× 70 0.7× 70 929
Keiko Misawa Japan 13 36 0.1× 40 0.3× 97 0.7× 101 0.8× 36 0.4× 25 518
Luis Aparicio Spain 15 163 0.6× 42 0.3× 28 0.2× 204 1.6× 34 0.3× 48 503
Vassilios Didilis Greece 10 129 0.5× 28 0.2× 28 0.2× 208 1.7× 23 0.2× 32 601
Shigeru Momiki Japan 10 197 0.7× 52 0.4× 21 0.2× 246 2.0× 32 0.3× 28 537
Yusuke Wada Japan 9 100 0.3× 113 0.8× 31 0.2× 198 1.6× 18 0.2× 42 496
Xianghua Yi China 14 236 0.8× 21 0.2× 68 0.5× 206 1.6× 111 1.1× 64 700
Bojun Wang China 16 301 1.1× 16 0.1× 187 1.4× 668 5.3× 86 0.9× 34 1.1k

Countries citing papers authored by Simon Chivers

Since Specialization
Citations

This map shows the geographic impact of Simon Chivers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Chivers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Chivers more than expected).

Fields of papers citing papers by Simon Chivers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Chivers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Chivers. The network helps show where Simon Chivers may publish in the future.

Co-authorship network of co-authors of Simon Chivers

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Chivers. A scholar is included among the top collaborators of Simon Chivers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Chivers. Simon Chivers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zammarchi, Francesca, Karin Havenith, Narinder Janghra, et al.. (2024). ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies. Molecular Cancer Therapeutics. 23(4). 520–531. 6 indexed citations
2.
3.
Rider, David A., et al.. (2022). Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease. Toxicological Sciences. 189(2). 237–249. 9 indexed citations
4.
Zammarchi, Francesca, et al.. (2020). CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. Journal for ImmunoTherapy of Cancer. 8(2). e000860–e000860. 55 indexed citations
5.
6.
Hartley, John A., Michael Flynn, John P. Bingham, et al.. (2018). Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Scientific Reports. 8(1). 10479–10479. 85 indexed citations
7.
Zammarchi, Francesca, Karin Havenith, Simon Chivers, et al.. (2018). Abstract 2792A: Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors. Cancer Research. 78(13_Supplement). 2792A–2792A. 4 indexed citations
8.
Zammarchi, Francesca, Simon Corbett, Lauren Adams, et al.. (2018). ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 131(10). 1094–1105. 118 indexed citations
9.
Zammarchi, Francesca, Karin Havenith, Simon Chivers, et al.. (2018). Abstract 744: ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors. Cancer Research. 78(13_Supplement). 744–744. 4 indexed citations
10.
Seefried, Lothar, Christine Hofmann, Erdmute Kunstmann, et al.. (2017). Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. Journal of Clinical Investigation. 127(6). 2148–2158. 57 indexed citations
11.
12.
Zammarchi, Francesca, Simon Chivers, Karin Havenith, et al.. (2017). Abstract 3111A: ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate cancers. Cancer Research. 77(13_Supplement). 3111A–3111A. 1 indexed citations
13.
Baumann, Andreas, Sven Kronenberg, Lolke de Haan, et al.. (2016). Non-clinical Safety Evaluation of Biotherapeutics – Challenges, Opportunities and new Insights. Regulatory Toxicology and Pharmacology. 80. S1–S14. 15 indexed citations
14.
Tankó, László B., Jörg Goldhahn, Aurore Varela, et al.. (2016). Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model?. Calcified Tissue International. 99(3). 310–321. 11 indexed citations
15.
Zammarchi, Francesca, Simon Chivers, David G. Williams, et al.. (2016). ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers. European Journal of Cancer. 69. S28–S28. 14 indexed citations
16.
Zammarchi, Francesca, Simon Corbett, Lauren Adams, et al.. (2016). hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies.. Blood. 128(22). 4176–4176. 12 indexed citations
17.
Zammarchi, Francesca, David G. Williams, Lauren Adams, et al.. (2015). Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies. Blood. 126(23). 1564–1564. 8 indexed citations
18.
Chapman, Kathryn, Simon Chivers, David Mitchell, et al.. (2014). Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies. Drug Discovery Today. 19(5). 528–532. 56 indexed citations
19.
Bowman, Christopher, William J. Breslin, Pauline L. Martin, et al.. (2013). Placental Transfer of Fc‐Containing Biopharmaceuticals across Species, an Industry Survey Analysis. Birth Defects Research Part B Developmental and Reproductive Toxicology. 98(6). 459–485. 32 indexed citations
20.
Guth, Brian D., Richard J. Briscoe, Simon Chivers, et al.. (2009). Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. Journal of Pharmacological and Toxicological Methods. 60(2). 107–116. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Winston Evering Breakdown of academic impact, for papers by Zhixin Qiu Breakdown of academic impact, for papers by H Makuuchi Breakdown of academic impact, for papers by Keiko Misawa Breakdown of academic impact, for papers by Luis Aparicio Breakdown of academic impact, for papers by Vassilios Didilis Breakdown of academic impact, for papers by Shigeru Momiki Breakdown of academic impact, for papers by Yusuke Wada Breakdown of academic impact, for papers by Xianghua Yi Breakdown of academic impact, for papers by Bojun Wang
Rankless by CCL
2026